Trince

Ottergemsesteenweg-Zuid 731

9000 Gent

BE

Trince

Foundation date

17/09/2021

Sector

#Supplier & Engineering

Subsector

Trince, a spin-off company from UGent is dedicated to delivering molecules into cells, both in vitro and ex vivo. Its LumiPore transfection platform combines laser exposure and nanoparticles to transiently permeabilize cell membranes. It can be used to deliver a wide variety of effector molecules into virtually any cell type, including hard-to-transfect cells. The high-throughput technology ensures efficient and gentle transfection, maximizing the therapeutic quality of the final cell product.

Upcoming events

Latest news

  • Bio Base Europe Pilot Plant successfully commissions a 75,000 L fermenter, demonstrating Vivici’s Vivitein™ BLG technology in industrial-scale precision fermentation

    17 hours ago

  • argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

    Wednesday November 20th 2024

  • ExeVir Announces Michael Garrett as New Chief Executive Officer

    Tuesday November 19th 2024